Pane wikiwiki
A monthly approval list tells a program sponsor nothing about their own sequence. It does not say whether the month's new products compete for the same synthes…
What Exactly Did the FDA Approve in September 2026, and How Is That Count Defined?
Peptide Manufacturer Wholesale Glp Peptide Nine novel drug approvals carry September 2026 dates on FDA’s novel drug approvals table for 2026, on a page current as of 9 ʻOkakopa 2026. The FDA defines novel drugs as “new drugs never before approved or marketed in the U.S.” (FDA’s novel drug approvals table for 2026, kiʻi ʻia 2026-10-09), so that table is a specific and narrow count.
Which of Those Approvals Are Peptides, Proteins, Radioligands, Gene Therapies, or Small Molecules?
Hōʻike nā huahana Radioligand i ka peptide-precursor, radiolabeling a me nā koi hoʻohele manawa. ʻAʻole ʻae ʻia kahi faila ANDA, a he a 505(b)(2) ʻAʻole he ANDA ka noi. E hōʻoia i ka ʻae a me ke ola o kēlā me kēia huahana mai kāna moʻolelo FDA ponoʻī ma mua o ka hoʻololi ʻana i ka lepili a Lutathera i kahi hōʻike ʻē aʻe..

E hoʻomaka me nā helu ʻelua e nānā i ka peptide-e pili ana a ʻaʻole. ʻO Apitegromab kahi antibody i hōʻike ʻia e CHO, ʻaʻole kahi peptide synthetic: he lambda IgG4 kanaka piha i hana ʻia i loko o nā pūnaewele ovary hamster Kina ma kahi ʻano 147 kDa (ʻO Isembyld e kuhikuhi ana i ka ʻike, 11 Kepakemapa 2026). ʻO ka insulin efsitora alfa kahi Fc-fusion insulin analog ma mua o ka mea maʻamau ʻO ka Polypeptide Synthesis peptide, i kūkulu ʻia mai kahi insulin kaulahao hoʻokahi, ʻelua mau loulou a me kahi ʻāpana IgG2 Fc kanaka ma 299 koena no ka monomer a pili 64 kDa (Onswik e kuhikuhi ana i ka ʻike, 23 Kepakemapa 2026). ʻO ka palena helu koena e hoʻokaʻawale i kahi peptide mai kahi protein fusion e noho ana ma 50 nā ʻakika amino, ka IUPAC a me ka FDA e hoʻohana ai i ka Fc-fusion i protein.
Was There a New Peptide Drug Approval in September, and What Is the Peptide-Relevant Signal?
ʻAʻole hiki i ka helu o kēlā me kēia mahina ke hoʻokumu i ke ʻano o ka noi no ka hana synthetic-peptide. ʻO nā protein pili i ka peptide recombinant a me nā radioligands peptide e hāpai pū i nā nīnau hana like ʻole mai kahi mea hana peptide i hoʻohuihui ʻia..
Mea Hana Mea Hoʻolako Peptides Ka noiʻi 1 Nā peptide
How Should a CMC Lead Read a Monthly Approval List When Planning Peptide Supply?

E heluhelu i ke kolamu ala ma mua o ke kolamu huahana, no ka mea, wānana ke ala i ka pūʻolo analytical e noi ʻia kahi polokalamu peptide e kākoʻo. ʻO nā paepae Pharmacopoeia ʻEulopa i hoʻohana ʻia ma o ke alakaʻi peptides synthetic EMA e koi i ka hōʻike ʻana ma luna. 0.1%, ʻike ma luna 0.5% a me ka pono ma luna 1.0%, a ua paʻa i nā mea haumia co-eluting i ka 1.0% paepae hōʻoia (EMA synthetic peptides alakaʻi, paʻi o kēia manawa). Noho nā peptides synthetic ma waho o ka ICH Q3A framework, no laila ke ʻōlelo nei kahi mea hoʻolako i ka Q3A no kahi ʻaoʻao haumia peptide i ka palapala hewa.
ʻElua mau hoʻohiki hou aʻe mai ka heluhelu like ʻana. Pono ka hōʻoia ʻana ma hope o ICH Q2(R2), hāpai ʻia ma Step 4 ma 1 Nowemapa 2023, ka mea no ka ho'āʻo haumia quantitative e uhi maʻamau i ka kikoʻī, laula, palena palena haʻahaʻa, pololei a pololei (I Q2(R2), 2023). Pono ke kūpaʻa e hoʻokō i nā liʻiliʻi liʻiliʻi he ʻumikūmālua mahina lōʻihi a me ʻeono mahina ma ka liʻiliʻi o ʻekolu mau pūʻulu kumu., me nā huahana i hoʻopaʻa ʻia ma ka 5°C a i ʻole 3°C (I Q1A(R2), 2003). ʻO nā palena Endotoxin no kahi peptide makua e hahai i ke ʻano K/M, me K ma 5 USP-EU/kg no kekahi ala ʻē aʻe ma waho o intrathecal (Mokuna Nui USP <85>, USP 35 kikokikona). ʻO ka peptide analytical characterization kahi e hoʻāʻo ʻia ai kēia mau palapala, a he mea nui wale ka papa inoa o kēlā me kēia mahina inā hoʻololi ʻo ia i ka mea o lākou e pono ai ka papahana.
Pono e heluhelu like ka nui o ka makeke. Manaʻo ʻo Grand View Research i ka 2025 peptide therapeutics market ma $140.9B, ke alakaʻi ʻia e ka insulin, Ua helu ʻia nā generics GLP-1 a me nā ʻāina ʻokoʻa (Noi Nui, 2026). ʻO ka peptide Purdue ka papa kuhikuhi, ka mea helu 51 mea hooikaika a 92 nā hui kākoʻo, ʻAʻole hōʻike nā helu i nā ʻae FDA kahiko a i ʻole nā hōʻike ʻē aʻe o US. kūʻai aku (CD, Ke Kulanui ʻo Purdue, lā ʻole). ʻO ka Octreotide 23 nā noi maʻamau e kūʻē 4 ʻO nā mea hou i loko o kēlā ʻōlelo kuhikuhi ka hōʻailona maopopo loa e lilo nā molekele peptide makua i mau ʻāpana piha a hiki mai nā ʻano hou ma ke ʻano he ʻae hoʻokahi.. Mea hoolako peptides
Nīnau pinepine
Was any peptide approved in September 2026?
ʻAʻohe peptide NME hou i ʻike ʻia ma Kepakemapa 2026 hoʻonoho. ʻO nā mea hoʻokomo pili ʻelua, apitegromab a me ka insulin efsitora alfa, he ʻano antibody IgG4 i hōʻike ʻia CHO a me kahi pūmua Fc-fusion (Onswik e kuhikuhi ana i ka ʻike, 23 Kepakemapa 2026).
Does a zero-peptide month signal falling peptide demand?
ʻAʻole. Ua ʻae ka FDA i hoʻokahi peptide ma nā mea āpau 2025, elamipretide ma 19 Kepakemapa (2025 FDA TIDES Ohi, 30 Ianuali 2026). ʻAʻole lawe ʻia ka zero o ka mahina hoʻokahi.
Ka hopena
ʻO ke kaʻina hana aʻe, ʻo ia ka lawe ʻana i hoʻokahi kaʻina o ka hoʻomohala ʻana a palapala ʻia e pili ana i nā palapala ma luna: ka 0.1, 0.5 a 1.0 pākēneka mau paepae haumia, ka ICH Q2(R2) hoʻonohonoho hōʻoia, ka ʻumikūmālua mahina a me ʻeono mahina paʻa liʻiliʻi, a me ka palena K/M endotoxin. Inā ʻaʻole hiki i ka pūʻolo data mea hoʻolako ke pane i kēlā mau helu ʻehā, ʻAʻole ʻo ka papa inoa ʻae ʻia i kēlā me kēia mahina ke kaohi.
E pili ana i ka mea hoʻopuka. ʻO MOL Changes kahi hui noiʻi a hoʻomohala e hāʻawi i nā lawelawe peptide, mai ka hoʻolālā kaʻina hana maʻamau a hiki i ka hana nui, a no laila he hoihoi pāʻoihana i ka ulu ʻana o ka noi hana peptide. Pono ka poʻe heluhelu e noʻonoʻo i kona manaʻo me ka noʻonoʻo. ʻAʻole pili ka alakaʻi i luna i kāna mau lawelawe.
